Key TakeawaysThe G-BA has determined that Efbemalenograstim alfa does not offer a therapeutic advantage over existing treatments like Lipegfilgrastim and Pegfilgrastim in managing...
Hemophilia A Treatment Faces New Challenges as G-BA Limits Efanesoctocog Alfa’s Market Advantage
Key TakeawaysThe G-BA has placed Efanesoctocog alfa in the Drug Cost Groups without recognizing any additional therapeutic benefit over existing recombinant factor VIII...
Osteoporosis Treatment Faces Challenges as G-BA Limits Abaloparatid’s Potential
MAT -
Key TakeawaysThe G-BA has ruled that Abaloparatid offers no significant advantage over established osteoporosis treatments, impacting its market potential for postmenopausal women at...
Etrasimod for Ulcerative Colitis: Costly Innovation Without Proven Superiority
MAT -
Key TakeawaysEtrasimod does not show additional therapeutic benefits over existing ulcerative colitis treatments based on current clinical trials.
The cost of Etrasimod is...
Vaccination Guidelines Reinforced as G-BA Upholds Current Recommendations for Pneumococcal Vaccines
Key TakeawaysThe G-BA's decision to uphold existing pneumococcal vaccination guidelines aligns with STIKO’s recommendations, emphasizing the importance of evidence-based practices in public health.
...
Pediatric Mucormycosis Treatment Advances: G-BA’s Assessment of Isavuconazole (Cresemba)
Key TakeawaysThe G-BA's benefit assessment of Isavuconazole (Cresemba) focuses on its efficacy and safety for treating pediatric mucormycosis, a rare but life-threatening fungal...
Amyotrophic Lateral Sclerosis Treatment Advances: Tofersen’s Impact on Survival and Quality of Life
Key TakeawaysThe G-BA's assessment of Tofersen highlights significant survival and quality of life improvements for amyotrophic lateral sclerosis patients with SOD1 mutations, particularly...
Key TakeawaysThe G-BA has initiated a new benefit assessment of Atezolizumab for non-small cell lung cancer patients with PD-L1 expression ≥ 50%, focusing...
Benign Prostatic Syndrome: G-BA Evaluates Water Vapor Ablation as a Promising Treatment Option
Key TakeawaysThe G-BA has initiated a formal consultation to assess the potential of water vapor ablation as a treatment for benign prostatic syndrome,...
Mammography Screening Program Overhaul Targets Women Aged 70-75
Key TakeawaysWomen aged 70-75 are now eligible for mammography screening in Germany.
Revised materials offer clearer data on breast cancer-specific mortality and overdiagnosis...
